Enicepatide

Phase 2

CCarmot Therapeutics, Inc.

Enicepatide is one of 2 therapeutic programs targeting Overweight or Obese. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight or ObeseActive, not recruiting

Overweight or ObesePhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Overweight or Obese

#DrugCompanyPhaseTrials

BGM0504

BBrightGene Bio-Medical Technology Co., Ltd.

Phase 2

1 2

Enicepatide

CCarmot Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Overweight or Obese

NCT06628362

Clinical

Trials by Indication[1]

Overweight or Obese1 trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Active, not recruiting·CCarmot Therapeutics, Inc.·Phase 2·NCT06628362·447 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enicepatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Enicepatide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Carmot Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCarmot Therapeutics, Inc.

Enicepatide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Overweight or Obese1 trial

References

Drug Info

Quick Facts

Related News